课题基金 / 基金详情

益气温阳方介导HMGB1/mTOR通路调控紧密连接蛋白治疗变应性鼻炎的机制研究

批准号:
82104939
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
顾文哲
依托单位:
学科分类:
中医耳鼻喉与口腔科学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
顾文哲

项目摘要

结项摘要

相似基金

相关文献

中文摘要
变应性鼻炎(AR)是与鼻粘膜屏障功能受损密切相关的耳鼻喉科常见慢性病,远期疗效并不理想,易反复发作。紧密连接(TJ)蛋白是维护粘膜屏障的重要结构。最新研究表明TJ蛋白受损导致鼻粘膜屏障功能被破坏是AR发病的重要病因;HMGB1/mTOR通路是介导自噬调控TJ蛋白的热门通路。益气温阳方是基于中医耳鼻喉科泰斗干祖望教授治疗AR经验形成的验方,疗效确切。本项目预实验发现AR患者鼻粘膜屏障受损,AR模型中自噬蛋白表达上调,TJ蛋白表达下调。益气温阳方给药干预后可逆转其结果。据此,提出本项目科学假说:益气温阳方调控HMGB1/mTOR通路信号通路抑制自噬稳定TJ蛋白治疗AR。本项目拟以C57BL/6小鼠、HNEpC构建的AR动物、细胞模型为实验对象,运用RNA干扰、免疫荧光等技术手段,对本项目假说的机制深入探讨,以进一步明确益气温阳方治疗AR的生物学基础,诠释“正气存内、邪不可干”治则的科学内涵。
英文摘要
Allergic rhinitis (AR) is a common chronic otolaryngology disease closely related to impaired nasal mucosal barrier function. At present, its long-term therapeutic effect is not ideal and it is prone to recurrent attacks. Tight junction (TJ) proteins are important structures for maintaining mucosal barrier. Recent studies have shown that damage of TJ proteins lead to disruption of nasal mucosal barrier function, which is an important cause of AR. And the HMGB1/mTOR pathway is a important pathway on mediating autophagy to regulate TJ proteins. Yiqiwenyang Formula is based on the treating AR experience of Professor Gan Zuwang, a leading otolaryngologist of Chinese medicine, which has definite clinical effect. The Pre-experiment of this project showed that the nasal mucosal barrier was damaged in AR patients. And the expression of autophagy-related proteins in AR models was up-regulated, while the expression of TJ-related proteins was down-regulated. The result could be reversed after the intervention of Yiqiwenyang Formula. Accordingly, the scientific hypothesis is put forward: Yiqiwenyang Formula inhibits autophagy to stabilize TJ proteins through HMGB1/mTOR signaling pathwayin the treatment of AR. The project intends to take the AR animal model constructed by C57BL/6 mice and cell model constructed by human nasal epithelial cells (HNEpC) as the experimental objects.The RNA interference, immunofluorescence and other techniques will be used to further explore the mechanism of this hypothesis. Through this project, the biological basis of YiFengYang Formula for AR treatment will be further clarified, and the scientific connotation of the TCM treatment principle of "positive qi stored inside, evil can not violate"will be more understood.
变应性鼻炎(AR)是临床常见病、多发病,远期疗效欠佳。鼻粘膜上皮细胞及紧密连接蛋白(TJ)是鼻腔防御的第一道防线,是鼻粘膜屏障主要组成部分,能阻止致敏原进入到粘膜下层。AR患者的鼻粘膜屏障存在着不同程度的损伤以及鼻粘膜细胞自噬的过度活化。保护鼻粘膜上皮细胞间的紧密连接对维护粘膜屏障功能和治疗AR至关紧要。目前已发现变应原促进鼻粘膜上皮细胞自噬下调TJ蛋白,进而破坏粘膜屏障功能是AR发生发展的重要机制。益气温阳方是依据国医大师干祖望对鼻炎病因病机认识而形成的中药验方,临床使用治疗AR疗效显著。本项目以益气温阳方为研究对象,通过构建小鼠AR动物模型、RPMI-2650鼻粘膜上皮细胞经HDM诱导AR细胞模型,首先观察了益气温阳方对AR的治疗效果,后续通过RNA干扰、免疫荧光等手段观察益气温阳方对自噬和TJ蛋白的影响,并验证了益气温阳方介导HMGB1/mTOR通路治疗AR的作用机制。结果显示造模后证实了AR疾病状态下TJ蛋白减少、鼻粘膜屏障被破坏,免疫荧光提示LC3B增多,自噬被激活。在益气温阳方给药后,改善AR模型鼠行为学评分,减轻鼻粘膜炎症损伤,减少杯状细胞数量,降低IgE含量,具有良好的治疗作用。免疫荧光等证实益气温阳方还能保护TJ蛋白,降低ROS、LC3B,透射电镜提示自噬小体给药后减少,鼻粘膜细胞自噬被抑制。并通过慢病毒转染敲低、过表达HMGB1等实验,证实了益气温阳方通过影响HMGB1/mTOR通路治疗AR。本项目研究最终证实了益气温阳方通过影响HMGB1/mTOR通路,抑制HMGB1表达,促进mTOR通路激活,抑制鼻粘膜细胞自噬,保护TJ蛋白,修复粘膜屏障治疗AR。本项目研究结果为益气温阳方的临床应用提供了科学依据,为其转化开发提供了参考。
国内基金
海外基金